RxDoctor Payments Data

Kevin Patel, MD

Neurology · Englewood, CONPI 1194013623

Payments from drug & device makers

$25,550in general payments, 2019–2025

Across 123 payments — averaging $207.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$10K
  • TG Therapeutics, Inc.$7K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Genentech, Inc.$1K
  • Novartis$970
  • Amgen$506
  • plus $441 from 7 others

What the payments were for

  • Consulting fees$21,72885%
  • Travel & lodging$1,5656%
  • Food & beverage$1,7357%
  • Education$5232%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,550 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$38,324
Medicare patients
153
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate77$664,664
Kesimpta PenOfatumumab24$241,159
EnspryngSatralizumab-Mwge13$197,478
TecfideraDimethyl Fumarate21$191,105
CopaxoneGlatiramer Acetate33$187,148
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5015$155,343
BetaseronInterferon Beta-1b11$124,660
Dalfampridine ErDalfampridine81$65,824
Glatiramer Acetate30$50,223
AmpyraDalfampridine11$47,078
Teriflunomide48$44,517
Dimethyl Fumarate48$12,311
Baclofen105$4,352
Gabapentin93$2,354
Lidocaine14$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$319$855,77098 claims
Genentech USA, Inc.Enspryng$10,021$197,47813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →